



BRITISH COLUMBIA  
CENTRE *for* EXCELLENCE  
*in* HIV/AIDS

# B.C. HIV/AIDS Drug Treatment Program

Monthly Report

May 2023





© 2023 BC Centre for Excellence in HIV/AIDS

**DISCLAIMER:** This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

### **BC Centre for Excellence in HIV/AIDS Drug Treatment Program**

St. Paul's Hospital  
687 - 1081 Burrard Street  
Vancouver, BC  
V6Z 1Y6

Tel: 604.806.8515  
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677  
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222  
Website: [www.bccfe.ca](http://www.bccfe.ca)  
Email: [info@bccfe.ca](mailto:info@bccfe.ca)

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





## EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to people living with HIV throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





### TABLE OF CONTENTS

#### 1. List of Figures

- 1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

#### 2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2022 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





## Table of Contents, cont'd...

### 3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

### 4. Health Authority Tables

#### INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribers in BC-CfE Registries

#### FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribers in BC-CfE Registries

#### VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribers in BC-CfE Registries

#### VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribers in BC-CfE Registries

#### NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribers in BC-CfE Registries

#### ABORIGINAL

- 4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at birth

### 5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority

May 2023

N = 7598



Health Authority	Male	Female	All
FRASER	1530	475	2005
INTERIOR	466	116	582
NORTHERN	151	81	232
VANCOUVER COASTAL	3304	445	3749
VANCOUVER ISLAND	834	166	1000
	<b>6285</b>	<b>1283</b>	<b>7568</b>
		<b>Unknown/not stated:</b>	<b>30</b>
		<b>Total:</b>	<b>7598</b>

Definitions:

**On antiretroviral therapy** defined as being on treatment in the current month


**Unknown/not stated** defined as being on treatment in the current month, and city of residence unknown

**Male & Female** refer to Sex at birth





### 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (May 2018 - May 2023)




**Notes:**

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month





### 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (May 2018 - May 2023)




**Notes:**

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month






1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants  
(May 2018 - May 2023)






1.5 BC-CfE Enrolment: New Antiretroviral Participants  
(May 2018 - May 2023)






1.6 Percent Distribution of Active Participants by CD4 Count  
(May 2018 - May 2023)






1.7 Percent Distribution of Inactive Participants by CD4 Count  
(May 2018 - May 2023)






### 1.8 Active and Inactive Participants (May 2018 - May 2023)






### 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (May 2018 - May 2023)






### 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (May 2018 - May 2023)






### 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(May 2018 - May 2023)






### 1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (May 2018 - May 2023)






### 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(May 2018 - May 2023)






### 1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (May 2018 - May 2023)






### 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(May 2018 - May 2023)






### 1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (May 2018 - May 2023)






1.17 Distribution of Participants on Entry/Integrase Inhibitors  
at the time of first ARV Therapy by INGREDIENT

(May 2018 - May 2023)






1.18 Baseline CD4 for Antiretroviral First Starts (May 2018 - May 2023)






### 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART (May 2018 - May 2023)






### 1.20 Cumulative Resistance Testing Results by Resistance Category (May 2018 - May 2023)





### 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (May 2018 - May 2023)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2023  
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	31	4	0	4	1	880	4	<40	4
1988	32	4	0	4	1	450	4	<40	4
1989	30	49	1	50	24	510	47	<40	3
1990	29	50	1	51	27	510	51	<40	3
1991	29	36	3	39	15	520	39	<40	3
1992	29	52	5	57	23	610	54	<40	3
1993	28	114	14	128	70	550	124	<40	3
1994	26	65	12	77	45	540	70	<40	3
1995	26	118	20	138	66	570	123	<40	3
1996	24	304	48	352	184	565	320	<40	3
1997	22	261	30	291	157	560	261	<40	3
1998	22	175	38	213	134	575	197	<40	3
1999	21	150	41	191	117	600	172	<40	3
2000	22	116	25	141	77	620	124	<40	3
2001	21	108	26	134	74	555	123	<40	3
2002	20	118	24	142	83	580	134	<40	3
2003	20	134	26	160	94	560	146	<40	3
2004	19	141	36	177	113	640	164	<40	3
2005	18	173	40	213	129	670	188	<40	3
2006	17	163	37	200	123	640	182	<40	3
2007	16	229	43	272	167	640	252	<40	3
2008	15	270	58	328	210	650	293	<40	3
2009	14	296	62	358	221	620	325	<40	3
2010	13	251	67	318	199	660	291	<40	3
2011	12	311	67	378	233	700	342	<40	3
2012	11	256	64	320	190	730	295	<40	3
2013	10	246	67	313	188	680	285	<40	3
2014	9	262	45	307	180	740	279	<40	3
2015	8	253	45	298	167	680	265	<40	3
2016	7	231	53	284	166	715	250	<40	3
2017	6	201	30	231	148	690	216	<40	3
2018	5	180	51	231	145	760	207	<40	3

**Definitions:**

**On treatment** defined as being on ARV therapy in the specified month and not reported deceased

**Duration** defined as cumulative years on ARV therapy, excluding periods of treatment interruption

**Current CD4 and PVL tests** defined as tests done in the last 6 months (most recent)

**Current ARV** defined as number of ARV drugs in the current regimen





**2.1 Duration of ARV treatment in the Province of BC, 1987-2023  
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Current CD4 Median	Current PVL (n)	Current PVL Median	Current ARV Median
2019	4	218	42	260	166	690	234	<40	3
2020	3	174	52	226	156	740	198	<40	3
2021	2	184	33	217	134	655	200	<40	3
2022	1	267	49	316	210	675	294	<40	3
2023	0	131	28	159	145	500	158	<40	3
<b>Total:</b>		<b>6295</b>	<b>1283</b>	<b>7578</b>					

**Definitions:**

**On treatment** defined as being on ARV therapy in the specified month and not reported deceased

**Duration** defined as cumulative years on ARV therapy, excluding periods of treatment interruption

**Current CD4 and PVL tests** defined as tests done in the last 6 months (most recent)

**Current ARV** defined as number of ARV drugs in the current regimen





## 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2022	7465	756	1878	<40	1317	650
FEB-2022	7386	774	1803	<40	1263	620
MAR-2022	7458	766	1904	<40	1251	620
APR-2022	7420	778	1755	<40	1153	620
MAY-2022	7477	763	1998	<40	1306	620
JUN-2022	7482	759	1839	<40	1201	630
JUL-2022	7495	754	1761	<40	1141	645
AUG-2022	7493	758	1990	<40	1227	620
SEP-2022	7443	771	1787	<40	1091	640
OCT-2022	7469	777	1849	<40	1163	640
NOV-2022	7502	783	1898	<40	1201	630
DEC-2022	7544	787	1607	<40	1004	630
JAN-2023	7583	793	2051	<40	1311	650
FEB-2023	7524	807	1727	<40	1009	630
MAR-2023	7553	803	1976	<40	1195	640
APR-2023	7560	796	1763	<40	1069	630
MAY-2023	7598	791	1931	<40	1187	650

**Definitions:**

**Active patient** defined as being on ARV treatment in the specified month

**Therapy days** defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

**PVL and CD4 tests** defined as tests done in the specified month





### 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2022	786	273	55	<40	45	580
FEB-2022	856	232	73	<40	56	635
MAR-2022	800	285	94	<40	73	480
APR-2022	834	278	70	<40	53	550
MAY-2022	758	317	60	<40	43	490
JUN-2022	761	291	61	<40	43	400
JUL-2022	764	283	61	<50	35	453
AUG-2022	786	262	59	78	49	560
SEP-2022	843	209	71	<40	53	460
OCT-2022	826	217	83	<40	61	500
NOV-2022	813	213	80	50	60	505
DEC-2022	778	236	57	<40	45	560
JAN-2023	737	289	63	<40	45	550
FEB-2023	790	234	66	<40	53	550
MAR-2023	756	246	76	<40	54	510
APR-2023	759	239	64	<40	45	560
MAY-2023	730	245	66	<40	46	430

**Definitions:**

**Inactive patient** defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs), and had contact with program in past 5 years

**Days off therapy** defined as number of days elapsed since last ARV treatment

**PVL and CD4 tests** defined as tests done in the specified month





2.4 BC-CfE Enrolment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2022	7432	786	19	7	161	144	2	14485
FEB-2022	7371	856	8	9	151	211	-61	14510
MAR-2022	7432	800	16	9	232	160	61	14539
APR-2022	7397	834	11	1	156	178	-35	14559
MAY-2022	7450	758	13	13	205	146	53	14583
JUN-2022	7457	761	11	15	178	170	7	14620
JUL-2022	7469	764	10	13	188	176	12	14659
AUG-2022	7469	786	15	17	169	171	0	14697
SEP-2022	7424	843	13	15	146	191	-45	14725
OCT-2022	7445	826	14	16	196	171	21	14760
NOV-2022	7481	813	9	17	209	177	36	14799
DEC-2022	7512	778	19	8	213	167	31	14826
JAN-2023	7553	737	20	10	194	143	41	14861
FEB-2023	7508	790	10	11	159	205	-45	14885
MAR-2023	7538	756	15	21	197	173	30	14919
APR-2023	7539	759	13	13	173	166	1	14947
MAY-2023	7578	730	7	15	200	165	39	14991

**Definitions:**

**Currently on ARV Therapy** defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

**Currently off ARV Therapy** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

**Deceased** defined as deceased in the specified month, and being on ARV treatment in the previous month

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Experienced Starts** defined as starting ARV treatment in the specified month, but previously being treated with ARVs

**New Inactive** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month, and had contact with the program in the past 5 years

**Net Change** is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





### 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2022	499	6468	455	43	<b>7465</b>	6.68%	86.64%	6.10%	0.58%	<b>100.00%</b>
FEB-2022	525	6371	445	45	<b>7386</b>	7.11%	86.26%	6.02%	0.61%	<b>100.00%</b>
MAR-2022	550	6408	455	45	<b>7458</b>	7.37%	85.92%	6.10%	0.60%	<b>100.00%</b>
APR-2022	567	6357	450	46	<b>7420</b>	7.64%	85.67%	6.06%	0.62%	<b>100.00%</b>
MAY-2022	597	6381	452	47	<b>7477</b>	7.98%	85.34%	6.05%	0.63%	<b>100.00%</b>
JUN-2022	614	6376	450	42	<b>7482</b>	8.21%	85.22%	6.01%	0.56%	<b>100.00%</b>
JUL-2022	634	6371	445	45	<b>7495</b>	8.46%	85.00%	5.94%	0.60%	<b>100.00%</b>
AUG-2022	643	6366	441	43	<b>7493</b>	8.58%	84.96%	5.89%	0.57%	<b>100.00%</b>
SEP-2022	663	6296	439	45	<b>7443</b>	8.91%	84.59%	5.90%	0.60%	<b>100.00%</b>
OCT-2022	679	6310	439	41	<b>7469</b>	9.09%	84.48%	5.88%	0.55%	<b>100.00%</b>
NOV-2022	696	6318	446	42	<b>7502</b>	9.28%	84.22%	5.95%	0.56%	<b>100.00%</b>
DEC-2022	709	6344	449	42	<b>7544</b>	9.40%	84.09%	5.95%	0.56%	<b>100.00%</b>
JAN-2023	721	6373	445	44	<b>7583</b>	9.51%	84.04%	5.87%	0.58%	<b>100.00%</b>
FEB-2023	735	6321	429	39	<b>7524</b>	9.77%	84.01%	5.70%	0.52%	<b>100.00%</b>
MAR-2023	750	6317	445	41	<b>7553</b>	9.93%	83.64%	5.89%	0.54%	<b>100.00%</b>
APR-2023	765	6313	441	41	<b>7560</b>	10.12%	83.51%	5.83%	0.54%	<b>100.00%</b>
MAY-2023	800	6322	435	41	<b>7598</b>	10.53%	83.21%	5.73%	0.54%	<b>100.00%</b>

**Definitions:**

**Number of Drugs** is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





**2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT**

	lamivudine		abacavir		zidovudine		tenofovir <TAF>		tenofovir <TDF>		emtricitabine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2022	3 20%	3064 42%	3 20%	2480 34%	0 0%	19 0%	12 80%	2922 40%	0 0%	1473 20%	12 80%	4262 58%
FEB-2022	6 24%	3019 42%	3 12%	2410 33%	2 8%	19 0%	15 60%	2939 41%	4 16%	1395 19%	19 76%	4225 58%
MAR-2022	3 10%	3034 41%	2 7%	2406 33%	0 0%	19 0%	24 83%	3029 41%	2 7%	1350 18%	26 90%	4272 58%
APR-2022	4 20%	3019 41%	3 15%	2366 33%	0 0%	19 0%	14 70%	3052 42%	2 10%	1313 18%	16 80%	4250 58%
MAY-2022	4 17%	3026 41%	3 13%	2354 32%	0 0%	18 0%	17 74%	3145 43%	2 9%	1282 17%	19 83%	4309 59%
JUN-2022	5 14%	3015 41%	0 0%	2309 31%	0 0%	19 0%	29 81%	3199 44%	4 11%	1237 17%	31 86%	4320 59%
JUL-2022	4 10%	3007 41%	3 8%	2285 31%	0 0%	19 0%	27 69%	3229 44%	9 23%	1218 17%	35 90%	4343 59%
AUG-2022	5 14%	2992 41%	4 11%	2262 31%	0 0%	18 0%	29 78%	3271 45%	3 8%	1178 16%	32 86%	4353 59%
SEP-2022	4 14%	2953 40%	3 11%	2196 30%	0 0%	17 0%	19 68%	3284 45%	5 18%	1173 16%	24 86%	4352 60%
OCT-2022	6 17%	2951 40%	4 11%	2174 30%	0 0%	16 0%	29 83%	3350 46%	0 0%	1143 16%	29 83%	4388 60%
NOV-2022	7 18%	2948 40%	5 13%	2158 29%	0 0%	15 0%	26 68%	3387 46%	6 16%	1136 15%	31 82%	4417 60%
DEC-2022	4 15%	2951 40%	3 11%	2148 29%	1 4%	16 0%	18 67%	3446 47%	5 19%	1109 15%	23 85%	4445 60%
JAN-2023	6 17%	2972 40%	1 3%	2148 29%	1 3%	16 0%	23 66%	3491 47%	8 23%	1096 15%	29 83%	4466 60%
FEB-2023	3 13%	2945 40%	1 4%	2098 28%	0 0%	17 0%	18 75%	3503 47%	3 13%	1067 14%	21 88%	4448 60%
MAR-2023	2 6%	2937 40%	2 6%	2072 28%	0 0%	15 0%	27 79%	3552 48%	5 15%	1054 14%	32 94%	4480 60%
APR-2023	3 11%	2951 40%	1 4%	2070 28%	0 0%	15 0%	23 82%	3552 48%	3 11%	1032 14%	25 89%	4473 60%
MAY-2023	10 24%	2945 39%	4 10%	2047 27%	1 2%	16 0%	30 71%	3598 48%	3 7%	1042 14%	32 76%	4515 61%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





**2.7 Number of Participants on Protease Inhibitor by INGREDIENT**

	fosamprenavir		atazanavir		darunavir		lopinavir		ritonavir		tipranavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2022	0 0%	1 0%	0 0%	476 29%	0 0%	1132 68%	0 0%	60 4%	0 0%	1 0%	0 0%	1 0%
FEB-2022	0 0%	1 0%	1 33%	447 28%	1 33%	1110 69%	1 33%	60 4%	0 0%	1 0%	0 0%	1 0%
MAR-2022	0 0%	1 0%	0 0%	430 27%	2 100%	1113 70%	0 0%	57 4%	0 0%	1 0%	0 0%	1 0%
APR-2022	0 0%	1 0%	0 0%	424 27%	0 0%	1085 69%	0 0%	56 4%	0 0%	1 0%	0 0%	1 0%
MAY-2022	0 0%	1 0%	1 33%	417 27%	2 67%	1080 70%	0 0%	53 3%	0 0%	1 0%	0 0%	1 0%
JUN-2022	0 0%	1 0%	0 0%	407 27%	1 100%	1056 70%	0 0%	52 3%	0 0%	1 0%	0 0%	1 0%
JUL-2022	0 0%	1 0%	0 0%	405 27%	1 100%	1039 70%	0 0%	50 3%	0 0%	1 0%	0 0%	1 0%
AUG-2022	0 0%	1 0%	0 0%	386 26%	1 100%	1028 70%	0 0%	45 3%	0 0%	1 0%	0 0%	1 0%
SEP-2022	0 0%	0 0%	0 0%	368 26%	2 100%	1010 71%	0 0%	44 3%	0 0%	1 0%	0 0%	1 0%
OCT-2022	0 0%	0 0%	0 0%	355 25%	0 0%	1002 72%	0 0%	44 3%	0 0%	1 0%	0 0%	1 0%
NOV-2022	0 0%	0 0%	0 0%	352 25%	6 100%	995 72%	0 0%	43 3%	0 0%	1 0%	0 0%	1 0%
DEC-2022	0 0%	0 0%	0 0%	341 24%	1 100%	1008 72%	0 0%	45 3%	0 0%	1 0%	0 0%	1 0%
JAN-2023	0 0%	0 0%	0 0%	339 25%	1 100%	994 72%	0 0%	44 3%	0 0%	1 0%	0 0%	1 0%
FEB-2023	0 0%	0 0%	0 0%	321 24%	0 0%	955 73%	0 0%	43 3%	0 0%	1 0%	0 0%	1 0%
MAR-2023	0 0%	0 0%	0 0%	317 24%	1 100%	953 73%	0 0%	42 3%	0 0%	1 0%	0 0%	1 0%
APR-2023	0 0%	0 0%	0 0%	305 23%	1 100%	959 74%	0 0%	42 3%	0 0%	1 0%	0 0%	1 0%
MAY-2023	0 0%	0 0%	0 0%	304 23%	2 100%	953 74%	0 0%	40 3%	0 0%	1 0%	0 0%	1 0%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





**2.8 Number of Participants on Non-Nucleosides by INGREDIENT**

	doravirine		efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2022	0 0%	103 9%	0 0%	328 30%	0 0%	130 12%	0 0%	317 29%	0 0%	235 21%
FEB-2022	0 0%	106 10%	0 0%	317 29%	0 0%	127 12%	0 0%	306 28%	1 100%	228 21%
MAR-2022	0 0%	113 11%	1 100%	303 28%	0 0%	132 12%	0 0%	301 28%	0 0%	222 21%
APR-2022	1 50%	124 12%	1 50%	301 28%	0 0%	130 12%	0 0%	297 28%	0 0%	223 21%
MAY-2022	0 0%	136 13%	0 0%	287 27%	0 0%	128 12%	0 0%	290 27%	1 100%	220 21%
JUN-2022	1 33%	149 14%	1 33%	284 27%	0 0%	122 12%	0 0%	285 27%	1 33%	211 20%
JUL-2022	0 0%	155 15%	1 33%	280 27%	0 0%	117 11%	0 0%	280 27%	2 67%	207 20%
AUG-2022	0 0%	157 15%	1 33%	275 27%	0 0%	119 12%	0 0%	274 27%	2 67%	204 20%
SEP-2022	0 0%	167 16%	3 100%	271 27%	0 0%	110 11%	0 0%	273 27%	0 0%	200 20%
OCT-2022	0 0%	173 17%	0 0%	261 26%	0 0%	105 10%	0 0%	269 27%	0 0%	196 20%
NOV-2022	1 33%	183 18%	2 67%	261 26%	0 0%	108 11%	0 0%	269 26%	0 0%	197 19%
DEC-2022	0 0%	186 19%	1 25%	254 25%	0 0%	107 11%	1 25%	262 26%	2 50%	195 19%
JAN-2023	3 43%	192 19%	4 57%	247 25%	0 0%	107 11%	0 0%	255 26%	0 0%	191 19%
FEB-2023	0 0%	202 20%	0 0%	250 25%	0 0%	98 10%	0 0%	249 25%	0 0%	190 19%
MAR-2023	0 0%	209 21%	0 0%	243 25%	0 0%	101 10%	0 0%	246 25%	0 0%	186 19%
APR-2023	1 50%	215 22%	1 50%	232 24%	0 0%	96 10%	0 0%	245 25%	0 0%	187 19%
MAY-2023	1 33%	223 23%	0 0%	233 24%	0 0%	99 10%	0 0%	239 24%	2 67%	187 19%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Doravirine not currently available on BC-CfE Formulary





**2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT**

	bictegravir		cabotegravir		dolutegravir		elvitegravir		fostemsavir		maraviroc		raltegravir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2022	11 73%	2421 43%	0 0%	0 0%	2 13%	2468 44%	1 7%	347 6%	0 0%	0 0%	0 0%	24 0%	1 7%	374 7%
FEB-2022	15 71%	2443 44%	0 0%	0 0%	6 29%	2437 44%	0 0%	331 6%	0 0%	0 0%	0 0%	21 0%	0 0%	369 7%
MAR-2022	23 85%	2536 45%	0 0%	0 0%	3 11%	2460 43%	1 4%	324 6%	0 0%	0 0%	0 0%	21 0%	0 0%	370 7%
APR-2022	14 74%	2574 45%	0 0%	0 0%	5 26%	2436 43%	0 0%	312 5%	0 0%	0 0%	0 0%	20 0%	0 0%	366 6%
MAY-2022	17 77%	2666 46%	0 0%	0 0%	5 23%	2455 43%	0 0%	309 5%	0 0%	0 0%	0 0%	22 0%	0 0%	360 6%
JUN-2022	29 85%	2710 47%	0 0%	0 0%	5 15%	2454 42%	0 0%	300 5%	0 0%	0 0%	0 0%	22 0%	0 0%	352 6%
JUL-2022	24 69%	2745 47%	0 0%	0 0%	7 20%	2452 42%	3 9%	297 5%	0 0%	0 0%	0 0%	22 0%	1 3%	342 6%
AUG-2022	26 76%	2790 48%	0 0%	0 0%	6 18%	2452 42%	1 3%	294 5%	0 0%	0 0%	1 3%	22 0%	1 3%	340 6%
SEP-2022	19 76%	2820 48%	0 0%	0 0%	6 24%	2433 42%	0 0%	281 5%	0 0%	0 0%	0 0%	21 0%	0 0%	323 6%
OCT-2022	28 80%	2889 49%	0 0%	0 0%	6 17%	2440 41%	1 3%	280 5%	0 0%	0 0%	0 0%	22 0%	0 0%	314 5%
NOV-2022	24 73%	2920 49%	0 0%	0 0%	8 24%	2462 41%	1 3%	276 5%	0 0%	1 0%	0 0%	22 0%	0 0%	309 5%
DEC-2022	16 70%	2974 50%	0 0%	0 0%	5 22%	2465 41%	1 4%	270 4%	0 0%	1 0%	0 0%	20 0%	1 4%	307 5%
JAN-2023	23 82%	3016 50%	0 0%	0 0%	5 18%	2493 41%	0 0%	269 4%	0 0%	1 0%	0 0%	21 0%	0 0%	302 5%
FEB-2023	18 75%	3041 50%	0 0%	0 0%	6 25%	2477 41%	0 0%	255 4%	0 0%	1 0%	0 0%	21 0%	0 0%	288 5%
MAR-2023	25 74%	3085 51%	0 0%	0 0%	5 15%	2484 41%	2 6%	259 4%	0 0%	1 0%	0 0%	20 0%	2 6%	291 5%
APR-2023	21 81%	3086 50%	0 0%	0 0%	4 15%	2500 41%	1 4%	258 4%	0 0%	1 0%	0 0%	18 0%	0 0%	275 4%
MAY-2023	28 67%	3138 51%	1 2%	3 0%	12 29%	2506 41%	1 2%	250 4%	0 0%	1 0%	0 0%	18 0%	0 0%	280 5%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





### 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category

MON-YYYY	Boosted PI + 2 N(t)RTIs		NNRTI + 2 N(t)RTIs		INSTI + 2 N(t)RTIs		2 drugs from 2 classes		IV 3 drugs from IV 3 classes		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2022	985	13.19	773	10.35	4452	59.64	496	6.64	673	9.02	86	1.15
FEB-2022	958	12.97	750	10.15	4409	59.69	522	7.07	667	9.03	80	1.08
MAR-2022	934	12.52	737	9.88	4482	60.10	548	7.35	673	9.02	84	1.13
APR-2022	908	12.24	725	9.77	4473	60.28	565	7.61	669	9.02	80	1.08
MAY-2022	898	12.01	709	9.48	4527	60.55	595	7.96	668	8.93	80	1.07
JUN-2022	873	11.67	705	9.42	4558	60.92	612	8.18	658	8.79	76	1.02
JUL-2022	857	11.43	698	9.31	4578	61.08	632	8.43	654	8.73	76	1.01
AUG-2022	829	11.06	691	9.22	4610	61.52	641	8.55	648	8.65	74	0.99
SEP-2022	800	10.75	691	9.28	4575	61.47	662	8.89	641	8.61	74	0.99
OCT-2022	789	10.56	673	9.01	4620	61.86	678	9.08	636	8.52	73	0.98
NOV-2022	770	10.26	682	9.09	4639	61.84	694	9.25	645	8.60	72	0.96
DEC-2022	773	10.25	663	8.79	4681	62.05	706	9.36	650	8.62	71	0.94
JAN-2023	751	9.90	665	8.77	4729	62.36	718	9.47	648	8.55	72	0.95
FEB-2023	716	9.52	665	8.84	4714	62.65	733	9.74	625	8.31	71	0.94
MAR-2023	700	9.27	654	8.66	4738	62.73	748	9.90	643	8.51	70	0.93
APR-2023	706	9.34	653	8.64	4740	62.70	762	10.08	634	8.39	65	0.86
MAY-2023	709	9.33	646	8.50	4754	62.57	797	10.49	626	8.24	66	0.87

**Definitions:**

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month





**2.11 Baseline CD4 for Antiretroviral First Starts**

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2022	7	1	0	1	1	3	490
FEB-2022	9	0	1	0	1	5	530
MAR-2022	9	4	1	1	1	2	150
APR-2022	1	0	0	0	0	1	820
MAY-2022	13	4	1	1	1	6	490
JUN-2022	15	1	4	1	4	4	400
JUL-2022	13	1	4	3	2	2	225
AUG-2022	17	1	3	3	2	5	330
SEP-2022	15	1	0	3	6	4	405
OCT-2022	16	0	0	1	5	9	520
NOV-2022	17	1	2	2	5	6	445
DEC-2022	8	1	1	2	0	1	320
JAN-2023	10	2	2	2	2	2	285
FEB-2023	11	2	2	3	1	3	253
MAR-2023	21	0	0	4	3	11	530
APR-2023	13	1	3	1	2	5	400
MAY-2023	15	2	1	2	5	2	374

**Definitions:**

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Baseline CD4** is defined as most recent CD4 test before ARV start





**2.12 DTP Participants with PVL Measurement within previous five years, and never on ART**

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2022	12277	3734
FEB-2022	12300	3748
MAR-2022	12328	3763
APR-2022	12357	3788
MAY-2022	12348	3777
JUN-2022	12363	3779
JUL-2022	12389	3788
AUG-2022	12410	3800
SEP-2022	12429	3809
OCT-2022	12455	3829
NOV-2022	12463	3819
DEC-2022	12440	3801
JAN-2023	12448	3803
FEB-2023	12436	3788
MAR-2023	12444	3788
APR-2023	12419	3755
MAY-2023	12427	3733

**Definitions:**

**Patients with PVL test** are defined as having at least one PVL test within previous five years, and not reported deceased/moved


**Never on ART** are subset of patients with PVL test, and not being treated with ARVs on or before specified month






3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants N = 7598  
May-2023

BY HEALTH SERVICES DELIVERY AREA




BY HEALTH AUTHORITY






3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participant  
May-2023

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




KELOWNA BY POSTAL CODE






3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participant  
May-2023

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




SURREY BY POSTAL CODE






3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participant  
May-2023

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VANCOUVER BY POSTAL CODE






3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participant  
May-2023

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VICTORIA BY POSTAL CODE






3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participant  
May-2023

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





### 4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>	<b>45</b>	<b>61</b>	<b>26</b>
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HSDA:</b>	<b>72</b>	<b>100</b>	<b>54</b>	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HSDA:</b>	<b>438</b>	<b>596</b>	<b>326</b>	
THOMPSON/CARIBOO/ SHUSWAP	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HSDA:</b>	<b>236</b>	<b>316</b>	<b>176</b>	
<b>Total HA:</b>		<b>791</b>	<b>1073</b>	<b>582</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HA:</b>		<b>791</b>	<b>1073</b>	<b>582</b>

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	162	220	116
Male	629	853	466

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	582	56	660	<40

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





### 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	26	*
	5 years or more	14	*
	<5 years	5	*
	<b>Total HSDA:</b>	<b>45</b>	<b>26</b>
KOOTENAY BOUNDARY	10 years or more	47	32
	5 years or more	12	10
	<5 years	13	12
	<b>Total HSDA:</b>	<b>72</b>	<b>54</b>
OKANAGAN	10 years or more	278	206
	5 years or more	87	62
	<5 years	73	58
	<b>Total HSDA:</b>	<b>438</b>	<b>326</b>
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	145	111
	5 years or more	44	30
	<5 years	47	35
	<b>Total HSDA:</b>	<b>236</b>	<b>176</b>
<b>Total HA:</b>		<b>791</b>	<b>582</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	496	364
	5 years or more	157	109
	<5 years	138	109
<b>Total HA:</b>		<b>791</b>	<b>582</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





### 4.3 Distribution of ARV Prescribers in BC-CfE Registries INTERIOR Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
EAST KOOTENAY	52	70	11	15
KOOTENAY BOUNDARY	79	138	23	46
OKANAGAN	238	1083	52	346
THOMPSON/CARIBOO/SHUSWAP	150	566	35	146
<b>Total:</b>	<b>519</b>	<b>1857</b>	<b>121</b>	<b>553</b>

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
EAST KOOTENAY	13
KOOTENAY BOUNDARY	12
OKANAGAN	69
THOMPSON/CARIBOO/SHUSWAP	47
<b>Total:</b>	<b>141</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Prescriber out of HA** is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





#### 4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	7	7	5
	20-34	35	37	27
	35-49	102	105	69
	50+	264	367	198
	<b>Total HSDA:</b>	<b>408</b>	<b>516</b>	<b>299</b>
FRASER NORTH	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>	<b>1148</b>	<b>1553</b>	<b>870</b>
FRASER SOUTH	0-19	9	9	8
	20-34	107	109	80
	35-49	303	330	238
	50+	630	959	510
	<b>Total HSDA:</b>	<b>1049</b>	<b>1407</b>	<b>836</b>
<b>Total HA:</b>		<b>2605</b>	<b>3476</b>	<b>2005</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	17	17	14
	20-34	279	284	207
	35-49	763	818	577
	50+	1546	2357	1207
<b>Total HA:</b>		<b>2605</b>	<b>3476</b>	<b>2005</b>

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	630	805	475
Male	1975	2671	1530

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	2005	53	655	<40

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





#### 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration FRASER Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	273	207
	5 years or more	67	39
	<5 years	68	53
	<b>Total HSDA:</b>	<b>408</b>	<b>299</b>
FRASER NORTH	10 years or more	715	521
	5 years or more	235	182
	<5 years	198	167
	<b>Total HSDA:</b>	<b>1148</b>	<b>870</b>
FRASER SOUTH	10 years or more	650	507
	5 years or more	209	162
	<5 years	190	167
	<b>Total HSDA:</b>	<b>1049</b>	<b>836</b>
<b>Total HA:</b>		<b>2605</b>	<b>2005</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1638	1235
	5 years or more	511	383
	<5 years	456	387
<b>Total HA:</b>		<b>2605</b>	<b>2005</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





#### 4.6 Distribution of ARV Prescribers in BC-CfE Registries FRASER Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
FRASER EAST	149	538	34	62
FRASER NORTH	261	1622	43	223
FRASER SOUTH	226	1805	47	498
<b>Total:</b>	<b>636</b>	<b>3965</b>	<b>124</b>	<b>783</b>

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
FRASER EAST	200
FRASER NORTH	714
FRASER SOUTH	478
<b>Total:</b>	<b>1392</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Prescriber out of HA** is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth  
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>354</b>	<b>525</b>
RICHMOND	20-34	27	28	16
	35-49	57	58	45
	50+	120	176	100
	<b>Total HSDA:</b>	<b>204</b>	<b>262</b>	<b>161</b>
VANCOUVER	0-19	13	13	10
	20-34	437	452	296
	35-49	1229	1366	865
	50+	2985	5327	2144
	<b>Total HSDA:</b>	<b>4664</b>	<b>7158</b>	<b>3315</b>
<b>Total HA:</b>		<b>5222</b>	<b>7945</b>	<b>3749</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	14	14	11
	20-34	493	509	330
	35-49	1361	1507	966
	50+	3354	5915	2442
<b>Total HA:</b>		<b>5222</b>	<b>7945</b>	<b>3749</b>

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	594	962	445
Male	4626	6981	3304
Unknown	2	2	0

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	3749	56	660	<40

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	237	182
	5 years or more	59	47
	<5 years	58	44
	<b>Total HSDA:</b>	<b>354</b>	<b>273</b>
RICHMOND	10 years or more	124	95
	5 years or more	33	24
	<5 years	47	42
	<b>Total HSDA:</b>	<b>204</b>	<b>161</b>
VANCOUVER	10 years or more	3244	2249
	5 years or more	814	586
	<5 years	606	480
	<b>Total HSDA:</b>	<b>4664</b>	<b>3315</b>
<b>Total HA:</b>		<b>5222</b>	<b>3749</b>

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	3605	2526
5 years or more	906	657
<5 years	711	566
<b>Total HA:</b>	<b>5222</b>	<b>3749</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribers in BC-CfE Registries  
VANCOUVER COASTAL Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH SHORE/COAST GARIBALDI	188	419	40	53
RICHMOND	45	315	9	97
VANCOUVER	684	11698	212	5438
<b>Total:</b>	<b>917</b>	<b>12432</b>	<b>261</b>	<b>5588</b>

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
<b>Total:</b>	<b>77</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Prescriber out of HA** is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth  
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>359</b>	<b>524</b>
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>126</b>	<b>178</b>
SOUTH VANCOUVER ISLAND	20-34	69	75	49
	35-49	192	218	147
	50+	542	863	416
	<b>Total HSDA:</b>	<b>803</b>	<b>1156</b>	<b>612</b>
<b>Total HA:</b>		<b>1288</b>	<b>1858</b>	<b>1000</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HA:</b>		<b>1288</b>	<b>1858</b>	<b>1000</b>

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	216	316	166
Male	1072	1542	834

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	1000	56	600	<40

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	217	177
	5 years or more	77	54
	<5 years	65	56
	<b>Total HSDA:</b>	<b>359</b>	<b>287</b>
NORTH VANCOUVER ISLAND	10 years or more	88	69
	5 years or more	24	19
	<5 years	14	13
	<b>Total HSDA:</b>	<b>126</b>	<b>101</b>
SOUTH VANCOUVER ISLAND	10 years or more	496	365
	5 years or more	163	127
	<5 years	144	120
	<b>Total HSDA:</b>	<b>803</b>	<b>612</b>
<b>Total HA:</b>		<b>1288</b>	<b>1000</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	801	611
	5 years or more	264	200
	<5 years	223	189
<b>Total HA:</b>		<b>1288</b>	<b>1000</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribers in BC-CfE Registries  
VANCOUVER ISLAND Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
CENTRAL VANCOUVER ISLAND	203	930	68	164
NORTH VANCOUVER ISLAND	160	283	39	69
SOUTH VANCOUVER ISLAND	224	1942	37	588
<b>Total:</b>	<b>587</b>	<b>3155</b>	<b>144</b>	<b>821</b>

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
CENTRAL VANCOUVER ISLAND	113
NORTH VANCOUVER ISLAND	43
SOUTH VANCOUVER ISLAND	123
<b>Total:</b>	<b>279</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Prescriber out of HA** is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth  
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	20-34	8	8	*
	35-49	17	20	*
	50+	28	36	*
	<b>Total HSDA:</b>	<b>53</b>	<b>64</b>	<b>30</b>
NORTH WEST	20-34	*	5	0
	35-49	*	39	19
	50+	*	77	37
	<b>Total HSDA:</b>	<b>73</b>	<b>121</b>	<b>56</b>
NORTHERN INTERIOR	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>	<b>197</b>	<b>296</b>	<b>146</b>
<b>Total HA:</b>		<b>323</b>	<b>481</b>	<b>232</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HA:</b>		<b>323</b>	<b>481</b>	<b>232</b>

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	115	176	81
Male	208	305	151

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	232	53	550	<40

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration  
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	31	*
	5 years or more	6	*
	<5 years	16	*
	<b>Total HSDA:</b>	<b>53</b>	<b>30</b>
NORTH WEST	10 years or more	52	39
	5 years or more	11	10
	<5 years	10	7
	<b>Total HSDA:</b>	<b>73</b>	<b>56</b>
NORTHERN INTERIOR	10 years or more	105	77
	5 years or more	58	43
	<5 years	34	26
	<b>Total HSDA:</b>	<b>197</b>	<b>146</b>
<b>Total HA:</b>		<b>323</b>	<b>232</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	188	130
	5 years or more	75	56
	<5 years	60	46
<b>Total HA:</b>		<b>323</b>	<b>232</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribers in BC-CfE Registries  
NORTHERN Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH EAST	39	60	6	8
NORTH WEST	88	179	17	38
NORTHERN INTERIOR	123	502	23	191
<b>Total:</b>	<b>250</b>	<b>741</b>	<b>46</b>	<b>237</b>

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
NORTH EAST	5
NORTH WEST	22
NORTHERN INTERIOR	13
<b>Total:</b>	<b>40</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Prescriber out of HA** is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





### 4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at Birth

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	5	11	*
	KOOTENAY BOUNDARY	6	9	*
	OKANAGAN	32	52	*
	THOMPSON/CARIBOO/SHUSWAP	27	52	*
	<b>Total HA:</b>	<b>70</b>	<b>124</b>	<b>51</b>
FRASER	FRASER EAST	36	51	29
	FRASER NORTH	50	93	40
	FRASER SOUTH	82	119	59
	<b>Total HA:</b>	<b>168</b>	<b>263</b>	<b>128</b>
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	25	52	22
	RICHMOND	6	11	5
	VANCOUVER	451	904	363
	<b>Total HA:</b>	<b>482</b>	<b>967</b>	<b>390</b>
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	47	82	38
	NORTH VANCOUVER ISLAND	15	29	11
	SOUTH VANCOUVER ISLAND	49	96	40
	<b>Total HA:</b>	<b>111</b>	<b>207</b>	<b>89</b>
NORTHERN	NORTH EAST	10	14	5
	NORTH WEST	33	69	25
	NORTHERN INTERIOR	71	118	54
	<b>Total HA:</b>	<b>114</b>	<b>201</b>	<b>84</b>
<b>Total:</b>		<b>945</b>	<b>1762</b>	<b>742</b>

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	600	1132	465
Female	345	630	277

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total:</b>	742	53	530	<40

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





## 5.1 Drug Names and Definitions

**Abacavir:** a NUCLEOSIDE ANALOG from ViiV Healthcare.

**Active:** persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

**Antiretroviral:** a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

**Atazanavir (Reyataz):** a PROTEASE INHIBITOR from Bristol-Myers Squibb.

**Atovaquone (Mepron):** a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

**Atripla:** the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

**Azithromycin (Zithromax):** an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

**Bictegravir:** an INTEGRASE INHIBITOR from Gilead Sciences.

**Boosted PI:** a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

**Cabenuva:** the ViiV Healthcare trade name for an injectable formulation containing CABOTEGRAVIR and RILPIVIRINE.

**Cabotegravir:** an INTEGRASE INHIBITOR.

**CD4 Cell Count:** the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

**Chemokine Receptor Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

**Clarithromycin (Biaxin):** an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

**Cobicistat:** a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

**Combination Therapy:** initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

**Complera:** the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

**Darunavir (Prezista):** a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**Deceased:** persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

**Descovy:** the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.





## Monthly Report

**Didanosine (Videx):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Dolutegravir (Tivicay):** an INTEGRASE INHIBITOR from ViiV Healthcare.

**Doravirine:** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Merck.

**Efavirenz (Sustiva, Auro efavirenz):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

**Elvitegravir:** an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

**Emtricitabine:** a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

**Enfuvirtide (Fuzeon):** a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

**Entry Inhibitor:** a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

**Etravirine (Intence):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**First started program:** a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

**Fosamprenavir (Telzir):** a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

**Fostemsavir:** an ATTACHMENT INHIBITOR from ViiV Healthcare. Fostemsavir is a PRODRUG of TEMSAVIR.

**Fusion Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

**Genvoya:** the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

**Health Authority:** refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

**Inactive:** persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

**Integrase Inhibitor:** a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

**Kivexa:** the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

**Lamivudine:** a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

**Lopinavir (Kaletra):** a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

**Maraviroc (Celsentri):** a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

**Median (MED) age:** median age of participants in the HIV/AIDS Drug Treatment program in that time period.





**MDRT:** see MULTIPLE DRUG RESCUE THERAPY

**Moved out of BC:** a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

**Multiple Drug Rescue Therapy (MDRT or Mega-HAART):** the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

**Nelfinavir (Viracept):** a PROTEASE INHIBITOR from ViiV Healthcare.

**Net change:** the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

**Nevirapine (Viramune):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

**NNRTI:** see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

**NNRTI / no PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

**Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI):** a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

**N(t)RTI:** a category of drug encompassing both NUCLEOSIDE ANALOG and NUCLEOTIDE ANALOG

**Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI):** a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

**Nucleotide Analog:** ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

**Odefsey:** the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

**One or more PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

**Other:** an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

**Pentamidine:** an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

**PI:** see PROTEASE INHIBITOR.

**Prezcobix:** the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

**Prodrug:** a compound that is converted within the body into the active form that has medical effects.

**Protease Inhibitor:** a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.





## Monthly Report

**Raltegravir (Isentress):** an INTEGRASE INHIBITOR from Merck.

**Restarted/ changed therapy (Tx):** a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

**Rifabutin (Mycobutin):** an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

**Rilpivirine (Edurant):** a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

**Ritonavir (Norvir):** a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

**Stavudine (Zerit):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Stopped all therapies (Tx):** a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

**Stribild:** the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

**Tenofovir alafenamide (Tenofovir AF, TAF):** a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

**Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF):** a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

**Tipranavir (Aptivus):** a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

**Triple Therapy:** the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

**Triumeq:** the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

**Trizivir:** the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

**Truvada:** the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.

**Valganciclovir:** an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

**Viral Load:** the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

**Zidovudine (Retrovir):** a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

